

### REMARKS

Claims 1 and 27-55 are pending, with claims 1, 32, 38, 44, and 50 being independent. Claims 2-26 were previously cancelled and claims 27, 28, 30, 33, 34, 36, 39, 40, 42, 45, 46, 48, 50-52, and 54 have been amended. Support for the amendments may be found in the application at, for example, page 19, lines 7-22. No new matter has been introduced.

### Allowable Subject Matter

Applicant acknowledges with appreciation the Examiner's allowance of claims 1, 29, 31, 32, 35, 37, 38, 41, 43, 44, 47, 49, 50, 53, and 55.

### Interview Summary

Applicant thanks Examiner Yamnitzky for the telephonic interview with applicant's representative, Hussein Akhavannik, conducted on February 17, 2009. During the interview, proposed amendments in response to the 35 U.S.C. § 112, second paragraph rejection of claims 27, 28, 30, 33, 34, 36, 39, 40, 42, 45, 46, 48, 51, 52, and 54 were discussed. The proposed amendments have been incorporated into claims 27, 28, 30, 33, 34, 36, 39, 40, 42, 45, 46, 48, 51, 52, and 54, as reflected above in the "Listing of Claims."

### Claim Rejections – 35 U.S.C. § 112

Claims 27, 28, 30, 33, 34, 36, 39, 40, 42, 45, 46, 48, 51, 52, and 54 have been rejected under 35 U.S.C. § 112, second paragraph as allegedly being indefinite.

Specifically, the Office Action contends that the variable "x" recited in claims 27, 28, 33, 34, 39, 40, 45, 46, 51, and 52 is not defined. Claims 27, 33, 39, 45, and 51 have been amended to replace "SiH<sub>x</sub>" with "silane." Claims 28, 34, 40, 46, and 52 have amended to replace "SiO<sub>x</sub>" with "silicon oxide."

In addition, the Office Action contends that the scopes of a quinoline bone structure, a benzoxazole bone structure, and a benzothiazole bone structure are not clear. Claims 30, 36, 42, 48, and 54 have been amended to recite a "quinoline structure," a "benzoxazole structure," and a "benzothiazole structure."

Accordingly, in view of these amendments, applicant respectfully requests reconsideration and withdrawal of the rejection of claims 27, 28, 30, 33, 34, 36, 39, 40, 42, 45, 46, 48, 51, 52, and 54.


Conclusion

Applicant submits that all claims are in condition for allowance.

It is believed that all of the pending issues have been addressed. However, the absence of a reply to a specific rejection, issue or comment does not signify agreement with or concession of that rejection, issue or comment. In addition, because the arguments made above may not be exhaustive, there may be reasons for patentability of any or all pending claims (or other claims) that have not been expressed. Finally, nothing in this reply should be construed as an intent to concede any issue with regard to any claim, except as specifically stated in this reply, and the amendment of any claim does not necessarily signify concession of unpatentability of the claim prior to its amendment.

The fee in the amount of \$810 in payment of the Request for Continued Examination fee is being paid concurrently herewith on the Electronic Filing System (EFS) by way of Deposit Account authorization. Please apply any other charges or credits due in connection with this filing or otherwise to deposit account 06-1050.

Respectfully submitted,



Hussein Akhavannik  
Reg. No. 59,347

Date: 2/17/2009

**Customer No. 26171**  
Fish & Richardson P.C.  
Telephone: (202) 783-5070  
Facsimile: (202) 783-2331